VOLITIONRX LTD 10-Q

ITEM 5. OTHER INFORMATION None. 33 ITEM 6. EXHIBITS Incorporated by Reference Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Filed Herewith 10.1 #† Common Stock Warrant issued by VolitionRx to Gael Forterre, dated January 1, 2021. 10-K 001-36833 10.18 03/22/21 10.2 #† Singapore Volition Pte. Limited Employment Agreement by and between Singapore Volition and Terig Hughes, dated January 27, 2021 and effective February 1, 2021, including the form of Common Stock Warrant attached as Schedule 2. 10-K 001-36833 10.19 03/22/21 10.3 #† Volition America, Inc. Employment Agreement by and between Volition America and Gael Forterre, dated February 1, 2021. 10-K 001-36833 10.20 03/22/21 10.4 #† Consulting Services Agreement by and between Volition Germany and 3F Management SPRL (Gaetan Michel), dated January 29, 2021; First Amendment to Consultancy Services Agreement between Volition Germany and 3F Management SPRL, dated February 1, 2021. 10-K 001-36833 10.21 03/22/21 10.5 Underwriting Agreement, dated February 10, 2021, by and between VolitionRx Limited and Cantor Fitzgerald & Co. 8-K 001-36833 1.1 02/12/21 10.6 #† Volition Veterinary Diagnostics Development, LLC Employment Agreement Chief Executive Officer, by and between Volition Vet and Salvatore Thomas Butera, dated March 25, 2021. X 10.7 #† Consulting Services Agreement by and between Volition Germany and 3F Management SPRL (Gaetan Michel), dated January 29, 2021; First Amendment dated February 1, 2021; Second Amendment dated May 1, 2021. X 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. X 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. X 32.1 * Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 34 101.INS XBRL Instance Document. X 101.SCH XBRL Taxonomy Extension Schema Document. X 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. X 101.LAB XBRL Taxonomy Extension Label Linkbase Document. X 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document. X 101.DEF XBRL Taxonomy Extension Definition Linkbase Document. X # Indicates a management contract or compensatory plan or arrangement. † Portions of this exhibit are redacted pursuant to Item 601(a)(6) and/or Item (b)(10)(iv) under Regulation S-K. The registrant agrees to furnish supplementally any omitted schedules to the SEC upon request. * The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing. 35 S I GNATURE S Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VOLITIONRX LIMITED Dated: May 11, 2021 By: /s/ Cameron Reynolds Cameron Reynolds President and Chief Executive Officer (Authorized Signatory and Principal Executive Officer) Dated: May 11, 2021 By: /s/ Terig Hughes Terig Hughes Chief Financial Officer and Treasurer (Authorized Signatory and Principal Financial and Accounting Officer) 36